文献速递中枢神经肿瘤放疗姑息放疗与转移瘤

美金刚减少儿童中枢神经系统肿瘤放疗后认知障碍:评估可行性的初步研究

Memantine to Reduce Cognitive Impairment After Radiation in Children: A Pilot Study Evaluating the Feasibility of Memantine in Reducing Cognitive Impairment in Pediatric Patients after Radiation Therapy for Central Nervous System Tumors.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2024-07-11

这项前瞻性单臂可行性研究纳入18例4至18岁接受颅内放疗的原发性中枢神经系统恶性肿瘤患者,给予6个月美金刚疗程。放疗后1个月时,17例可分析患者中9例达到100%服药依从性,16例中15例(94%)依从率超过80%。常见毒性为1至2级乏力、头痛和恶心,无归因于药物的3级及以上事件。

要点

  • 美金刚在儿童中枢神经系统肿瘤放疗患者中可行、安全且耐受良好。
  • 放疗后1个月,16例中15例(94%)服药依从率超过80%。
  • 最常见毒性为1至2级乏力、头痛和恶心,无归因的3级及以上事件。

核心结论

  • 美金刚是儿童中枢神经系统恶性肿瘤多模式治疗中可行、安全且耐受良好的添加治疗。
  • ACCL2031的结果有待明确美金刚在该人群中的价值。

研究设计与样本

  • 前瞻性单臂可行性研究,纳入2020年至2022年18例4至18岁接受颅内放疗的原发性中枢神经系统恶性肿瘤患者,排除世界卫生组织4级星形细胞瘤和胶质母细胞瘤。
  • 放疗期间及放疗后给予6个月美金刚疗程,剂量在4周内以5 mg递增,目标为基于体重的最大剂量(0.4 mg/kg至最接近的5 mg),不超过10 mg每日两次。
  • 主要终点为放疗后1个月时80%患者达到80%服药依从率;次要目标包括3个月和6个月时的美金刚可行性。

主要发现

  • 研究因避免与3期随机儿童肿瘤学组研究ACCL2031竞争而提前关闭,未达到预设停止规则。
  • 1例患者因使用改变认知的物质退出,余17例可分析;1例因恶心在首剂后停用美金刚。
  • 剩余16例患者放疗后1个月中位服药完成率为100%(范围74%-100%;17例中9例依从性100%),16例中15例(94%)依从率超过80%。
  • 放疗后3个月和6个月次要终点中位依从率分别为100%(范围55%-100%)和96%(范围33%-100%)。
  • 至少可能与研究药物相关的毒性事件(n=27)最常见为1至2级乏力、头痛和恶心,无归因于药物的3级及以上事件。

局限性

  • 研究因避免与3期随机儿童肿瘤学组研究ACCL2031竞争而提前关闭。
  • 1例患者因使用改变认知的物质退出,1例因恶心在首剂后停用美金刚。
  • ACCL2031的结果有待明确美金刚在该人群中的价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Memantine is standard in certain adults receiving brain radiation therapy (RT) to decrease cognitive impacts, but it is unknown whether pediatric patients can take, tolerate, and/or benefit from memantine. In this prospective single-arm feasibility study, we hypothesized that pediatric patients receiving central nervous system (CNS) RT would tolerate memantine with good adherence. METHODS AND MATERIALS: Patients aged 4 to 18 years with a primary CNS malignancy (excluding World Health Organization grade 4 astrocytoma, glioblastoma) receiving intracranial RT were eligible. A 6-month memantine course was given during and after RT, with dose titration in 5 mg increments over 4 weeks targeting a weight-based maximum (0.4 mg/kg to the closest 5 mg), not to exceed 10 mg twice a day. The primary endpoint was to achieve 80% drug adherence rate in 80% of patients measured 1 month after RT. Secondary objectives included memantine feasibility at 3 and 6 months. RESULTS: Eighteen patients enrolled from 2020 to 2022 and were prescribed memantine with RT. The study closed early to avoid competing with the phase 3 randomized Children's Oncology Group study ACCL2031. No predefined stopping rules were met. One patient withdrew for cognition-altering substance use, leaving 17 patients available for analysis. One patient discontinued memantine after one dose due to nausea. For the remaining 16 patients, there was a median of 100% pill completion rate (range, 74%-100%; n = 9/17 with 100% adherence) at 1 month after RT, with 15/16 (94%) with adherence rates >80%. At the 3- and 6-month post-RT time points for secondary endpoints, the median adherence rates were 100% (range, 55%-100%) and 96% (range, 33%-100%), respectively. Grade 1 to 2 fatigue, headache, and nausea were the most common toxicity events, at least possibly related to the study drug (n = 27), without attributable grade 3+ events. CONCLUSIONS: Memantine is a feasible, safe, and well-tolerated addition to multimodality treatment for pediatric CNS malignancies. Results of ACCL2031 are awaited to define the value of memantine in this population.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. McKone EL, Breen WG, Foster NR, et al. Memantine to Reduce Cognitive Impairment After Radiation in Children: A Pilot Study Evaluating the Feasibility of Memantine in Reducing Cognitive Impairment in Pediatric Patients after Radiation Therapy for Central Nervous System Tumors. Int J Radiat Oncol Biol Phys. 2024. PMID: 39001719. doi:10.1016/j.ijrobp.2024.05.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。